In the last trading session, 1.01 million shares of the Cara Therapeutics Inc (NASDAQ:CARA) were traded, and its beta was 0.68. Most recently the company’s share price was $0.29, and it changed around $0.02 or 9.77% from the last close, which brings the market valuation of the company to $15.82M. CARA currently trades at a discount to its 52-week high of $1.31, offering almost -351.72% off that amount. The share price’s 52-week low was $0.24, which indicates that the current value has risen by an impressive 17.24% since then. We note from Cara Therapeutics Inc’s average daily trading volume that its 10-day average is 0.46 million shares, with the 3-month average coming to 539.94K.
Cara Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.60. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 4 recommended CARA as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Cara Therapeutics Inc is expected to report earnings per share of -0.17 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cara Therapeutics Inc (NASDAQ:CARA) trade information
Instantly CARA has showed a green trend with a performance of 9.77% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.3000 on recent trading dayincreased the stock’s daily price by 3.33%. The company’s shares are currently down -60.70% year-to-date, but still up 0.41% over the last five days. On the other hand, Cara Therapeutics Inc (NASDAQ:CARA) is -15.36% down in the 30-day period. We can see from the shorts that 0.94 million shares have been sold at a short interest cover period of 2.2 day(s).
The consensus price target as assigned by Wall Street analysts is $1, which translates to bulls needing to increase their stock price by 71.0% from its current value. Analyst projections state that CARA is forecast to be at a low of $1 and a high of $1.
Cara Therapeutics Inc (CARA) estimates and forecasts
Cara Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -56.60 percent over the past six months and at a 43.38% annual growth rate that is well above the industry average of 17.10%. The year-over-year growth rate is expected to be -68.41%, down from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 1.6M in revenue for the current quarter. 1 analysts expect Cara Therapeutics Inc to make 1.2M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3M and 2.13M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -46.87%. Forecasts for the next quarter put sales growth at -43.79%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -1.20%.
CARA Dividends
Cara Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Cara Therapeutics Inc (NASDAQ:CARA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 15.74% of Cara Therapeutics Inc shares, and 28.16% of them are in the hands of institutional investors. The stock currently has a share float of 33.42%. Cara Therapeutics Inc stock is held by 91.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 4.1224% of the shares, which is about 2.25 million shares worth $0.58 million.
DISCIPLINED GROWTH INVESTORS INC /MN, with 3.546% or 1.94 million shares worth $0.5 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
